English

设为首页 | 加入收藏 | 联系我们

首页 >> 研究生教育 >> 导师介绍 >> 博士生导师

苑玉和

时间:2019/7/18 来源: 阅读:11035次


苑玉和

 

 

苑玉和,女,博士,博士生导师,研究员。

联系方式

电话:010-63165182

Emailyuanyuhe@imm.ac.cn

 

教育背景及工作经历

2002.09-2005.07中国协和医科大学基础医学研究所生物化学与分子生物学专业 博士

2005.08-至今 中国医学科学院药物研究所 药理室

 

专业研究领域

目前主要的研究方向是基于帕金森病(Parkinsons diseasePD)发病机制的新理论,研究治疗PD创新药物。根据目前主持的课题,具体研究内容如下:

1. 帕金森病发病机制研究:主要聚焦帕金森病相关基因,研究PD发病机制。目前主要基于神经炎症、脑-肠轴、朊蛋白样病变等学说,应用分子生物学技术与现代生物学技术,研究a-突触核蛋白(a-synuclein)和孤儿核受体Nurr1PD发生发展的关系与机制,为PD药物研究提供理论依据和技术支撑。

2. 抗帕金森病创新药物研究:以目前国际上研究PD发病机制的理论为指导,结合本课题组的研究基础,分别从分子、细胞和动物三个层面建立了多种PD药物筛选和评价模型,与药物所其它科室合作,共同研发PD创新药物。

 

发表论文(近五年)

[1]    Shao QH, Yan WF, Zhang Z, Ma KL, Peng SY, Cao YL, Yuan YH*, Chen NH*. Nurr1: A vital participant in the TLR4-NF-κB signal pathway stimulated by α-synuclein in BV-2 cells. Neuropharmacology.  2019, 144388-399

[2]    Chen Y, Zhang QS, Shao QH, Wang S, Yuan YH*, Chen NH*, Wang HB. NLRP3 inflammasome pathway is involved in olfactory bulb pathological alteration induced by MPTP.Acta Pharmacol Sin. 2019 Feb 6. doi: 10.1038/s41401-018-0209-1

[3]    Wang S, Yuan YH*, Chen NH*, Wang HBThe mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in Parkinson's disease. International Immunopharmacology 67 (2019) 458–464

[4]    Wen L# ,Zhang QS, Heng Y, Chen Y, Wang S, Yuan YH*, Chen NH*. NLRP3 inflammasome activation in the thymus of MPTP-induced Parkinsonian mouse model. Toxicol Lett. 2018, 5(288):1-8.

[5]    Shao QH, Zhang XL, Chen Y, Zhu CG, Shi JG, Yuan YH*, Chen NH*. Anti-neuroinflammatory effects of 20C from Gastrodia elata via regulating autophagy in LPS-activated BV-2 cells through MAPKs and TLR4/Akt/mTOR signaling pathways. Mol Immunol. 2018 May 12;99:115-123

[6]    Zhang QS, Heng Y, Chen Y, Luo P, Wen L, Zhang Z, Yuan YH*, Chen NH*. A novel bibenzyl compound, 20C, protected mice from MPTP/p toxicity by regulating alpha-synuclein related inflammatory response.J Pharmacol Exp Ther.  2018 May 12;99:115-123.

[7]    Zhang Q, Yang H, Mou Z, Huang JY, Yuan YH*, Chen NH. * Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease[J]. Acta Pharmacologica Sinica, 2017 Oct;38(10):1317-1328.

[8]    Shao QH, Zhang XL, Yang PF, Yuan YH*, Chen NH*.Amyloidogenic proteins associated with neurodegenerative diseases activate the NLRP3 inflammasome.Int Immunopharmacol. 2017;363(2):284-292.

[9]    Qiu-Shuang Zhanga, Yang Henga, Yu-He Yuan*, Nai-Hong Chen*. Pathological α-Synuclein Exacerbates the Progression of Parkinson’s Disease through Microglial Activation. Toxicol Lett 2017, 265(4) :30-37.

[10]Yang Heng, Qiu-Shuang Zhang, Zheng Mu, Jin-Feng Hu, Yu-He Yuan*, Nai-Hong Chen* Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting α-synuclein abnormalities in the substantia nigra, Toxicol Lett, 2016; 243:7-21

[11]Yuan YH, Yan WF, Sun JD, Huang JY, Mu Z, Chen NH*.The molecular mechanism of rotenone-induced α-synuclein aggregation: Emphasizing the role of the calcium/GSK3β pathway. Toxicol Lett, 2015; 233: 163-171.

[12]Yan WF, Shao QH, Zhang DM, Yuan YH*, Chen NH*. The molecular mechanism of polygalasaponin F-mediated decreases in TNF α: emphasizing the role of the TLR4-PI3K/AKT-NF-κB pathway. J Asian Nat Prod Res, 2015; 17: 662-670.

[13]Wu MM, Yuan YH, Chen J, Li CJ, Zhang DM, Chen NH*. Polygalasaponin F against rotenone-induced apoptosis in PC12 cells via mitochondria protection pathway. J Asian Nat Prod Res 2014; 16:59-69.

[14]Wei W, Yuan YH, Gao YN, Yan WF, Li CJ, Zhang DM, Chen NH*. Polygalasaponin F inhibits secretion of inflammatory cytokines via NF-kappaB pathway regulation. J Asian Nat Prod Res 2014; 16:865-875.

[15]Liu XY, Li CJ, Chen FY, Ma J, Wang S, Yuan YH, Li L, Zhang DM. Nototronesides A-C, Three Triterpene Saponins with a 6/6/9 Fused Tricyclic Tetranordammarane Carbon Skeleton from the Leaves of Panax notoginseng. Org Lett. 2018 ;20(15):4549-4553

[16]Yan JQ, Yuan YH, Chu SF, Li GH, Chen NH. E46K Mutant α-Synuclein Is Degraded by Both Proteasome and Macroautophagy Pathway. Molecules. 2018 Nov 1;23(11). pii: E2839. doi: 10.3390/molecules23112839

[17]Zhang XL, Yuan YH, Shao QH, Wang ZZ, Zhu CG, Shi JG, Ma KL, Yan X, Chen NH.DJ-1 regulating PI3K-Nrf2 signaling plays a significant role in bibenzyl compound 20C-mediated neuroprotection against rotenone-induced oxidative insult.Toxicol Lett. 2017271:74-83

[18]Mou Z, Yuan YH, Lou YX, Heng Y, Huang JY, Xia CY, Gao Y, Zhu CG, Chu SF, Luo P, Shi JG, Chen NH*. Bibenzyl compound 20c protects against endoplasmic reticulum stress in tunicamycin -treated PC12 cells in vitro. Acta Pharmacol Sin 2016 Dec;37(12):1525-1533

[19]Huang JY, Ma YZ, Yuan YH, Zuo W, Chu SF, Liu H, Du GH, Zhang DM, Chen NH*.Claulansine F promoted the neuronal differentiation of neural stem and progenitor cells through Akt/GSK-3β/β-catenin pathway. Eur J Pharmacol 2016; 786: 72-84

[20]Kong LL, Wang ZY, Hu JF, Yuan YH, Li H, Chen NH*. Inhibition of chemokine-like factor 1 improves blood-brain barrier dysfunction in rats following focal cerebral ischemia. Neurosci Lett 2016; 627: 192-198

[21]Yan JQ, Yuan YH, Gao YN, Huang JY, Ma KL, Gao Y, Zhang WQ, Guo XF, Chen NH*.Overexpression of human E46K mutant α-synuclein impairs macroautophagy via inactivation of JNK1-Bcl-2 pathway.Mol Neurobiol. 2014;50:685-701

[22]Ma KL, Song LK, Yuan YH, Zhang Y, Han N, Gao K, Chen NH*. The nuclear accumulation of alpha-synuclein is mediated by importin alpha and promotes neurotoxicity by accelerating the cell cycle.Neuropharmacology. 2014;82:132-42

[23]Ma KL, Song LK, Yuan YH, Zhang Y, Yang JL, Zhu P, Chen NH*.α-Synuclein is prone to interaction with the GC-box-like sequence in vitro. Cell Mol Neurobiol. 2014;34:603-9

[24]Song XY, Hu JF, Sun MN, Li ZP, Zhu ZX, Song LK, Yuan YH, Liu G, Chen NH* IMM-H004, a novel coumarin derivative compound, attenuates the production of inflammatory mediatory mediators in lipopolysaccharide-activated BV2 microglia.Brain Res Bull. 2014;106:30-8

[25]Song LK, Ma KL, Yuan YH, Mu Z, Song XY, Niu F, Han N, Chen NH*. Targeted Overexpression of α-Synuclein by rAAV2/1 Vectors Induces Progressive Nigrostriatal Degeneration and Increases Vulnerability to MPTP in Mouse. PLoS One 2015; 10: e0131281

[26]Liu Y, Sun JD, Song LK, Li J, Chu SF, Yuan YH, Chen NH*. Environment-contact administration of rotenone: A new rodent model of Parkinson’s disease. Behav Brain Res, 2015; 294: 149-161.

专著

1.      《应用分子药理学》主编:王晓良, 中国协和医科大学出版社出版,2015,参编;

2.      《现代药理实验方法》,主编:张均田杜冠华,中国协和医科大学出版社,2015,参编;

3.      《神经递质与神经疾患》主编:陈乃宏,中国协和医科大学出版社, 2012,参编。

 

专利

1. 专利名称:天麻中具有神经细胞保护活性的多聚苄类衍生物;申请人:中国医学科学院药物研究所;发明人:石建功,陈乃宏,王亚男,苑玉和,林生,吴苗苗,郭庆兰,朱承根;申请号:201210159421.X;申请日:2012-05-22

2. 专利名称:从北柴胡中提取的有效组分CHB及其抗抑郁活性的应用;申请人:中国医学科学院药物研究所;发明人:陈乃宏、秦海林、苑玉和、邓安珺、刘佳莉、于金倩、刘岩、李志宏;专利号:201210411794.1;申请日:2011-10-24

3. 专利名称:伸筋草碱A-C、其制法和其药物组合物与用途;申请人:中国医学科学院药物研究所;发明人:庾石山,陈乃宏,王晓婧、苑玉和、屈晶、马双刚、李勇;专利号:201110325450.4

4. 专利名称:伸筋草碱A-C、其制法和其药物组合物与用途;申请人:中国医学科学院药物研究所;发明人:庾石山,陈乃宏,王晓婧、苑玉和、屈晶、马双刚、李勇;专利号:201110325450.4,申请日:2011-10-24;国际专利PCT/CN2012/083360,申请日:2012-10-23

 

 

 

 

 

 

内部链接
相关链接